Pharming Group N.V. Sales And Marketing Expense
Pharming Group N.V. (PHAR) reported Sales And Marketing Expense of $131.00 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-04-02.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:SalesAndMarketingExpense · last filed 2026-04-02
EUR
| Period end | Sales And Marketing Expense 12 month |
|---|---|
| 2020-12-31 | 45.16M EUR 20-F · filed 2021-04-07 |
| 2019-12-31 | 39.91M EUR 20-F · filed 2021-04-07 |
| 2018-12-31 | 34.54M EUR 20-F · filed 2021-04-07 |
USD
| Period end | Sales And Marketing Expense 12 month |
|---|---|
| 2025-12-31 | $131.00M 20-F · filed 2026-04-02 |
| 2024-12-31 | $118.80M 20-F · filed 2026-04-02 |
| 2023-12-31 | $124.05M 20-F · filed 2026-04-02 |
| 2022-12-31 | $85.80M 20-F · filed 2025-04-03 |
| 2021-12-31 | $59.45M 20-F · filed 2024-04-04 |
| 2020-12-31 | $51.60M 20-F · filed 2023-04-05 |
| 2019-12-31 | $44.72M 20-F · filed 2022-04-06 |